Zogenix (ZGNX) Receiving Somewhat Positive Press Coverage, Study Shows
News coverage about Zogenix (NASDAQ:ZGNX) has trended somewhat positive on Tuesday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Zogenix earned a news impact score of 0.03 on Accern’s scale. Accern also gave media headlines about the company an impact score of 44.7399198834858 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Zogenix (NASDAQ ZGNX) opened at $37.60 on Tuesday. The stock has a market cap of $1,190.00, a P/E ratio of -8.56 and a beta of 1.96. Zogenix has a 12-month low of $7.70 and a 12-month high of $43.35. The company has a current ratio of 2.71, a quick ratio of 2.71 and a debt-to-equity ratio of 0.23.
Zogenix (NASDAQ:ZGNX) last released its quarterly earnings data on Tuesday, November 7th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.95) by ($0.16). Zogenix had a negative return on equity of 99.61% and a negative net margin of 309.76%. analysts anticipate that Zogenix will post -4.45 earnings per share for the current year.
A number of brokerages have recently weighed in on ZGNX. BidaskClub downgraded shares of Zogenix from a “buy” rating to a “hold” rating in a report on Thursday, January 11th. ValuEngine raised shares of Zogenix from a “sell” rating to a “hold” rating in a report on Saturday, September 30th. Mizuho reaffirmed a “buy” rating and set a $51.00 price target (up previously from $28.00) on shares of Zogenix in a report on Friday, September 29th. JMP Securities began coverage on shares of Zogenix in a report on Monday, November 27th. They set an “outperform” rating and a $56.00 price target for the company. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $50.00 price target (up previously from $20.00) on shares of Zogenix in a report on Monday, October 2nd. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Zogenix currently has an average rating of “Buy” and an average price target of $42.67.
In related news, EVP Bradley S. Galer acquired 1,346 shares of the stock in a transaction that occurred on Wednesday, December 13th. The stock was acquired at an average cost of $36.59 per share, for a total transaction of $49,250.14. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Roger Hawley sold 63,203 shares of the company’s stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $36.84, for a total transaction of $2,328,398.52. Following the transaction, the director now owns 105,575 shares of the company’s stock, valued at $3,889,383. The disclosure for this sale can be found here. 6.60% of the stock is owned by corporate insiders.
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with Analyst Ratings Network's FREE daily email newsletter.